BNET Industries
Last Fiscal Year Sales:$1.0B
- Private
- US
Dow Jones Description
Injectable Monoclonal Antibody-Based Pharmaceuticals Mfr & Developer for Cardiovascular, Infectious & Autoimmune Diseases
CFO & Vice President
Richard A. BierlyNumber of Employees 3,000
Peer Companies
NAICS Code In-Vitro Diagnostic Substance Manufacturing: 325413
Recent Events
-
Litigator of the Week: Dianne Elderkin of Woodcock Washburn
News & Analysis
Filter by
centocor inc. and schering-plough corp. - All News and Analysis
Centocor, Schering-Plough revise agreement covering REMICADE, Golimumab.
- 2007-12-01
Centocor, Inc. (Horsham, PA) and Schering-Plough Corporation (Kenilworth, NJ) have revised their 1998 distribution agreement regarding the development, commercialization and distribution of both REMICADE infliximab, an anti-tumor necrosis factor (anti-TNF) alpha therapy for chronic inflammatory disorders, and golimumab, Centocor's next-generation, human, anti-TNF alpha therapy, which...
New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms Of Ankylosing Spondylitis According to Phase 3 Study Findings
- 2007-11-08
Patients with Painful and Progressive Form of Inflammatory Spinal Arthritis Receiving Monthly Golimumab Treatment Showed Marked Improvements in Physical Function BOSTON -- More than half of patients receiving monthly subcutaneous SC injections of golimumab (CNTO 148) 50 mg and 100 mg experienced significant and sustained improvements in the signs...
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
- 2007-11-08
Golimumab Achieved Primary and Major Secondary Endpoints in the Largest Phase 3 Biologic Trial Completed to Date in Psoriatic Arthritis BOSTON -- Patients with active psoriatic arthritis receiving monthly subcutaneous SC injections of golimumab (CNTO 148) experienced significant and sustained improvements in the joint and skin manifestations of the...
Centocor, Inc. and Schering-Plough Corporation Announce Approval of First and Only Biologic Treatment for Pediatric Crohn's Disease.
- 2007-03-26
M2 PRESSWIRE-26 March 2007-Afternoon Movers: Centocor, Inc. and Schering-Plough Corporation Announce Approval of First and Only Biologic Treatment for Pediatric Crohn's DiseaseC1994-2007 M2 COMMUNICATIONS LTD RDATE:26032007 Schering-Plough (NYSE:SGP) is a global science-based health care company with leading prescription, consumer and...
REMICADE(R) Receives Approval in European Union for Dosing Flexibility in the Treatment of Rheumatoid Arthritis.
- 2007-03-02
HORSHAM, Pennsylvania., and KENILWORTH, New Jersey, March 2 /PRNewswire/ -- - Revised Labeling Will Allow RA Patients to Receive Adjusted Dosage To Maximize Efficacy and Symptom Relief Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP) today announced that the European Commission EC...
REMICADE(R) Receives Approval in European Union for Shortened Infusion Time in Patients With Rheumatoid Arthritis.
- 2006-12-14
HORSHAM, Pennsylvania and KENILWORTH, New Jersey, December 14 /PRNewswire/ -- Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP) today announced that the European Commission EC has approved a label extension for REMICADER infliximab allowing for a shortened infusion time in patients with rheumatoid arthritis...
Anti-TNF Golimumab (CNTO 148) Continues to Show Promise in Phase 2 Rheumatoid Arthritis Study.
- 2006-11-13
WASHINGTON, November 13 /PRNewswire/ -- - One-Year Data Presented at American College of Rheumatology Meeting Show Sustained Improvement in Signs and Symptoms of Moderately to Severely Active Rheumatoid Arthritis Nearly 75 percent of patients with moderately to severely active rheumatoid arthritis...
REMICADE(R) Receives Approval in European Union for Treatment of Moderate to Severe Plaque Psoriasis.
- 2005-10-06
MALVERN, Pennsylvania and KENILWORTH, New Jersey, October 6 /PRNewswire/ -- Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP) today announced that the European Commission has granted approval of REMICADE R infliximab for the treatment of moderate to severe plaque psoriasis. The new indication...
European Union CHMP Recommends Approval of REMICADE(R) for Treatment of Moderate-To-Severe Plaque Psoriasis.
- 2005-07-28
LEIDEN, Netherlands and BRUSSELS, Belgium, July 28 /PRNewswire/ -- Centocor B.V. and Schering-Plough Corporation (NYSE: SGP) today announced that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMEA issued a positive opinion recommending the approval of...
Remicade(R) Approved in European Union for Treatment of Psoriatic Arthritis.
- 2004-10-14
KENILWORTH, New Jersey and HORSHAM, Pennsylvania, October 14 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP) and Centocor, Inc. today announced that the European Commission has granted approval of REMICADER infliximab in the European Union EU, in combination with methotrexate, for the treatment of...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Richard A. Bierly | CFO & Vice President |
| Daniel Everitt | Vice President of Clinical Pharmacology and Global Pharmacovigilance |
| Ronald E. Schmid | Vice President, Corp Communications |
| William R Tolbert | Vice President |
| David P. Holveck | Director |
| Organization | Position | Status |
|---|---|---|
| Centocor, Inc. | CFO & Vice President | Current |
| Organization | Position | Status |
|---|---|---|
| Centocor, Inc. | Vice President of Clinical Pharmacology and Global Pharmacovigilance | Current |
| Institute for Oneworld Health | Board of Directors | Current |
| SmithKline Beecham Corporation | Director of Clinical Pharmacology | Former |
| Neuroscience, Inc | Group Director | Former |
| Organization | Position | Status |
|---|---|---|
| Centocor, Inc. | Vice President, Corp Communications | Current |
| Organization | Position | Status |
|---|---|---|
| Advanced Tissue Sciences, Inc. | Vice President | Current |
| Centocor, Inc. | Vice President | Current |
| Invitron Limited | Vice President | Current |
| Merchant-Taylor International, Inc | Senior Associate | Current |
David P. Holveck was appointed President, Chief Executive Officer, and a Director of Endo in April 2008. Prior to joining Endo, Mr. Holveck was President of Johnson & Johnson Development Corporation and Vice President, Corporate Development of Johnson & Johnson since 2004. Mr. Holveck joined Johnson & Johnson as a company Group Chairman in 1999, following the acquisition of Centocor, Inc., by Johnson & Johnson. Mr. Holveck was Chief Executive Officer of Centocor, Inc., at the time of the acquisition. Mr. Holveck joined Centocor in 1983 and progressed through various executive positions. In 1992, he assumed the role of President and Chief Operating Officer and later that year was named President and Chief Executive Officer. Prior to joining Centocor, he held positions at General Electric Company, Corning Glass Works, and Abbott Laboratories. Mr. Holveck is a member of the Board of Trustees for the Fund for West Chester University and the Board of Directors of the Eastern Technology Council as well as the Board of Directors of Light Sciences Oncology, Inc.
| Organization | Position | Status |
|---|---|---|
| Endo Pharmaceuticals Holdings Inc. | President & Chief Executive Officer | Current |
| Johnson & Johnson Development Corp. | Vice President, Corporate Development | Current |
| Tengion, Inc. | Current | |
| Biotechnology Industry Organization | board member | Current |
| Eastern Technology Council | Board Member | Current |
| Centocor, Inc. | Director | Current |
| University City Science Center | Board of Directors | Current |
| Light Sciences Oncology, Inc. | Board of Directors | Current |
| Liberty Science Center, Inc. | Board Member | Current |
| Endo Pharmaceuticals Holdings Inc. | Board of Directors | Current |
| Centocor, Inc. | Chief Executive Officer | Former |
| Johnson & Johnson | President, Corporate Development | Former |
| Centocor, Inc. | president | Former |
| Centocor, Inc. | chief operating officer | Former |
| General Electric Company | Team Member | Former |
| Abbott Laboratories | Team Member | Former |
| Corning Glass Works | Team Member | Former |
| Johnson & Johnson Development Corp. | President | Former |
| The Group Inc. | Chairman | Former |
| Johnson & Johnson Development Corp. | Company Group Chairman | Former |
| Johnson & Johnson | Company Group Chairman | Former |
| West Chester University | B.S. Degree In Education | Former |
Executive News
-
Endo Pharmaceuticals Introduces Valstar (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
-
FDA extends review on Endo drug
-
Endo Pharmaceuticals (ENDP) Says FDA Extends Review Date for Testosterone Treatment 9/3/2009
-
Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive...
-
Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
-
Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate...
-
Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate for Men with Hypogonadism
-
FDA taking more time to review Endo hypogonadism drug
-
Endo partners with ProStrakan to market testosterone transdermal gel
-
Endo to commercialize Fortesta in the U.S.
-
Endo licenses ProStrakan's testosterone gel Fortesta in US for up to $210 million
-
Endo buys rights to ProStrakan testosterone replacement gel Fortesta
-
Endo In Deal To Sell ProStrakan's Testosterone Gel In US
-
Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA(TM) in the U.S.
-
Biotech 2009 to Feature Endo Pharmaceuticals President and CEO, David P. Holveck, as Dinner...
-
Endo Pharmaceuticals's COO resigns
-
Endo Pharmaceuticals (ENDP) Announces Resignation of Chief Operating Officer
-
Endo Pharmaceuticals Announces Resignation of Chief Operating Officer
-
Endo Pharmaceuticals Announces Resignation of Chief Operating Officer
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
Glass Door
Centocor
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
